Reaction Is Overdone For PTC Therapeutics Pausing Huntington Trial Enrollment, Analyst Says
Earlier today, the FDA requested additional data to allow a 12-week portion of the Phase 2 PIVOT-HD study…
European Medicines Agency Committee For Medicinal Products For Human Use Adopts Opinion Recommending Authorization Of Moderna’s Omicron BA.4-BA.5 Targeting Bivalent Covid-19 Vaccine In The European Union
Positive recommendation follows the recent approval of Spikevax bivalent Original/Omicron BA.1 (mRNA-1273.214), a bivalent booster vaccine targeting the Omicron BA.1 subvariant, in September
CAMBRIDGE, MA / ACCESSWIRE /
Enanta Pharmaceuticals Presents New Preclinical Data For EDP-235, Its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed For The Treatment Of COVID-19 At IDWeek 2022 On October 21
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced new preclinical data supporting
BioVie Announces Phase 2 Trial Assessing NE3107’s Pro-motoric Activity In Parkinson’s Disease Is Fully Enrolled
BioVie Inc., (NASDAQ:BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and
FDA Injunctions Would Require The Companies And Named Individuals To Stop Manufacturing, Selling, And Distributing Their E-cigarettes; Injunctions Would Also Require The Defendants To Obtain Marketing Authorization From The FDA Before Marketing
FDA, DOJ Seek Permanent Injunctions Against Six E-cigarette Manufacturers | FDA
Caribou Biosciences Presents Case Report On Long-Term Follow Up Of First Patient Dosed In Phase 1 ANTLER Trial At The Lymphoma, Leukemia, & Myeloma Congress 2022 October 18-22
Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the presentation of a case report for long-term follow up on the first patient
Design Therapeutics To Present Preclinical Data Highlighting The Potential Of Its GeneTAC Small Molecule, DT-216, For The Treatment Of Friedreich Ataxia At International Congress for Ataxia Research 2022 November 3
Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that preclinical data for the company's novel
BridgeBio Pharma Highlights Its RAS Precision Oncology Portfolio And Shares Compelling Data From Next-Generation G12C Inhibitor And Novel PI3Kα:RAS Breaker Mechanism At The Fourth RAS Initiative Symposium
- BridgeBio to host investor call today (October 17, 2022) at 1:30 pm ET to discuss its two most advanced RAS precision oncology programs – KRASG12C GTP/GDP dual inhibitor development candidate